Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    K231733
    Date Cleared
    2024-02-09

    (241 days)

    Product Code
    Regulation Number
    870.2300
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    Neteera Technologies Ltd.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Neteera 130H-Plus device is intended for spot and continuous measurement of heart rate and respiration rate in adult patients (in healthcare facilities and home monitoring) and inform on bed exit.

    The indications provided are to be used by health care professionals and are intended to be reviewed by clinicians to inform patient care.

    The Neteera device is not intended to be used as an alarm system for potentially acute life-threatening situations in which medical intervention is necessary (e.g., ICU).

    Device Description

    Neteera 130H-Plus device is a modification of the predicate device Neteera 130H (K212143). It is a contact-free vital-signs monitor based on a high frequency (122.25-123 GHz) micro-radar on-chip and algorithm, capable of detecting Respiration Rate (RR) and Heart Rate (HR) during rest or subject's mild body movement, with the additional capability of identifying and notifying on bed exit.
    Neteera's micro- radar-based solution enables remote measurement, in real-time, in a non-invasive and contact-free manner. The system works by measuring only the ballistocardiograph micro-movements of of the skin (BCG) through nonmetallic materials such as furniture and clothing at a high resolution, and it has several different mounting options and measuring ranges.

    AI/ML Overview

    This FDA 510(k) summary provides information on the Neteera 130H-Plus Vital Sign Monitoring Sensor, which is a modification of a previously cleared device. The summary primarily focuses on demonstrating substantial equivalence to the predicate device rather than detailing comprehensive acceptance criteria and a standalone study for the current device. However, it does provide some clinical validation details.

    Here's an attempt to extract and interpret the information based on your requested format:

    1. A table of acceptance criteria and the reported device performance

    The document does not explicitly present a table of acceptance criteria with corresponding performance metrics for HR, RR, or bed exit detection. It states that "all outcomes met the same pre-specified performance criteria" from the predicate device's clearance, but these criteria are not detailed in this submission. To fully answer this, one would need to refer to the K212143 submission for the predicate device.

    However, based on general expectations for vital sign monitors, the reported measurement ranges can be inferred as indirectly related to performance.

    ParameterAcceptance Criteria (Inferred/Referenced)Reported Device Performance (Implied)
    Heart Rate (HR)Within range of 40-160 Beats Per Minute with performance comparable to FDA-cleared ECG reference.Met pre-specified performance criteria.
    Respiration Rate (RR)Within range of 5-40 Breaths Per Minute with performance comparable to FDA-cleared Capnograph reference.Met pre-specified performance criteria.
    Bed Exit DetectionNew feature; performance criteria not specified in this summary.Functioned as intended (implied by clearance).

    2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

    • Sample Size (Clinical Validation): 46 subjects.
    • Data Provenance: The study was a "GCP-compliant confirmatory clinical validation study under Independent Ethical Committee approval." This implies a prospective study. The country of origin is not explicitly stated, but the sponsor, Neteera Technologies Ltd., is based in Jerusalem, Israel, which might suggest the study was conducted there.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

    This information is not provided in the document. The ground truth was established by "FDA-cleared devices ECG and Capnograph," which are considered reference standards, not human experts for interpretation.

    4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

    This information is not applicable as the ground truth was established by FDA-cleared reference devices (ECG and Capnograph), not through human expert adjudication.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    • MRMC Study: No, an MRMC comparative effectiveness study was not done. This device is a standalone vital signs monitor, not an AI-assisted diagnostic tool for human readers.

    6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done

    • Standalone Performance: Yes, the clinical validation study was for the standalone performance of the Neteera 130H-Plus device, comparing its measurements directly against FDA-cleared reference devices (ECG and Capnograph). The device is described as "contact-free vital-signs monitor based on a high frequency (122.25-123 GHz) micro-radar on-chip and algorithm."

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

    • Type of Ground Truth: Measurements from FDA-cleared reference devices: ECG (for Heart Rate) and Capnograph (for Respiration Rate).

    8. The sample size for the training set

    This information is not provided in the 510(k) summary. The summary focuses on the clinical validation of the modified device, not its initial algorithm development or training data.

    9. How the ground truth for the training set was established

    This information is not provided in the 510(k) summary.

    Ask a Question

    Ask a specific question about this device

    K Number
    K212143
    Date Cleared
    2022-09-28

    (446 days)

    Product Code
    Regulation Number
    870.2300
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    Neteera Technologies Ltd.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Neteera 130H/131H device is intended for spot and continuous measurement of heart rate and respiration rate in adult patients (in healthcare facilities and home monitoring).

    The indications provided are to be used by health care professionals and are intended to be reviewed by clinicians to inform patient care.

    The Neteera device is not intended to be used as an alarm system for potentially acute life-threatening situations in which medical intervention is necessary (e.g., ICU).

    Device Description

    Neteera 130H/131H device is a contact-free vital-signs monitor based on a high frequency (122.25-123 GHz) micro-radar on-chip and algorithm, capable of detecting a variety of parameters: Respiration Rate (RR), Heart Rate (HR), during rest or subject's mild body movement.
    Neteera's micro radar-based solution enables measuring the micro-motions of the skin (BCG-Ballistocardiograph) remotely, in a real-time, non-invasive, and non-contact manner, through non-metallic materials such as furniture and clothing at a high resolution.

    AI/ML Overview

    The Neteera 130H/131H Vital Signs Monitoring Sensor is intended for "spot and continuous measurement of heart rate and respiration rate in adult patients (in healthcare facilities and home monitoring)." The following details describe the acceptance criteria and the study that proves the device meets them:

    1. Table of Acceptance Criteria and Reported Device Performance

    The acceptance criteria are implied by the performance metrics reported, specifically the percentage of measurements falling "under 10% error" or meeting "5% or 5bpm Criteria" for HR, and "under 10% error or 2brpm" for RR. These thresholds represent the satisfactory performance levels.

    ParameterSubgroupNum. Setups HRNum. Setups RRSpot HR under 10% errorSpot HR 5% or 5bpm CriteriaSpot RR under 10% error or 2brpmContinuous HR under 10% errorContinuous HR 5% or 5bpm CriteriaContinuous RR under 10% error or 2brpm
    Chair BackTotal13013098.46%96.92%96.15%97.44%95.96%93.1%
    Chair FrontTotal13013198.46%96.92%96.95%98.7%97.33%93.52%
    Above BedPart 2343497.06%97.06%91.18%96.44%95.28%93.1%
    All Front (Chair & Bed)16416598.17%96.95%95.76%98.26%96.94%93.44%

    2. Sample Size for the Test Set and Data Provenance

    The clinical validation study involved 170 subjects in total across two parts.

    • Part 1: 100 subjects from Israel.
    • Part 2: 70 subjects from the US population, specifically recruiting subjects with cardiopulmonary and metabolic medical disorders.

    The study was prospective as it was a "GCP-compliant clinical study."

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts

    No information is provided about the number of experts or their qualifications used to establish ground truth.

    4. Adjudication Method for the Test Set

    No information is provided about an adjudication method for the test set. Given that the ground truth for vital signs is typically established through direct measurement with reference devices, complex adjudication methods like 2+1 or 3+1 are typically not applicable.

    5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    A Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not conducted. The Neteera 130H/131H is a direct measurement device for vital signs, rather than an AI-assisted diagnostic tool that would typically involve human readers.

    6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done

    Yes, a standalone performance study was done. The performance results presented in the table are for the Neteera device's measurements compared to a reference device, indicating its standalone accuracy in measuring HR and RR. The device is described as "a high frequency (122.25-123 GHz) micro-radar on-chip and algorithm," implying autonomous measurement.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

    The ground truth for the performance testing was established using a reference medical device. Specifically, the "MindRay Patient Monitor, model ePM 10M (K200015)," which is an FDA-cleared device.

    8. The sample size for the training set

    The document does not specify the sample size for the training set. The provided clinical study data (170 subjects) appears to be for validation/testing, not training.

    9. How the ground truth for the training set was established

    The document does not provide information on how the ground truth for the training set, if any, was established. It only mentions the reference device used for validation.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1